^
Association details:
| Biomarker: | IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion |
|---|---|
| Cancer: | Oligodendroglioma |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
ADULT GLIOMA: OLIGODENDROGLIOMA (IDH-MUTANT, 1p19q CODELETED)….Recurrent or Progressive Disease WHO grade 2, KPS ≥60...Useful in Certain Circumstances...NTRK gene fusion tumors...Entrectinib
